Igenomix is a global leader in women’s health and reproductive genetic testing services for IVF clinics. The Company support c. 90,000 couples per year with a global footprint of 19 laboratories covering +80 countries.
Igenomix’s vision is to become the worldwide reference in reproductive medicine and women’s health. Over the last decade, the Company has positioned itself as an innovation leader, supported by world-class R&D, and has established a global footprint with a network of 19 labs across 16 countries. Igenomix has also developed a diversified portfolio of IVF genetic services covering all phases of the reproductive cycle: i) preconception, ii) pre-implantation; and iii) pre-natal. The Company is headquartered in Valencia, Spain and employs +390 people, of which c.18% hold a PhD and have contributed to +440 scientific publications.
Market trends and drivers
Strong secular growth in the IVF industry and in Igenomix’s core market segments are underpinned by increasing number of IVF cycles, increasing penetration of genetic testing and stable outsourcing rates. Leadership position supported by significant advantage in terms of R&D (42 publications in 2018, 4x main competitor) and proprietary product portfolio and pipeline, led by CSO and Founder, Carlos Simon, a world recognized scientist in this field.
Prior to the acquisition by EQT, Igenomix had built a strong financial profile and track-record, achieving consistent annual revenue growth and profitability. Supported by a scalable and sustainable business model, the Company has the opportunity to: i) continue building on attractive market growth while maintaining current profitability levels; ii) generate additional revenues from launch of new products driving market adoption and market share increases; and iii) capitalize on additional market opportunities by further expanding into new geographies. EQT will continue to support Igenomix in its pursuit to become the worldwide reference in reproductive medicine and women’s health.